JP2005536507A - ６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療 - Google Patents

６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療 Download PDF

Info

Publication number
JP2005536507A
JP2005536507A JP2004521592A JP2004521592A JP2005536507A JP 2005536507 A JP2005536507 A JP 2005536507A JP 2004521592 A JP2004521592 A JP 2004521592A JP 2004521592 A JP2004521592 A JP 2004521592A JP 2005536507 A JP2005536507 A JP 2005536507A
Authority
JP
Japan
Prior art keywords
pyrrolo
alkyl
pyridazine
mmol
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004521592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005536507A5 (enExample
Inventor
アンカー，ナオミ・バーク
アルーダ，ジーニー・エム
キヤンベル，ブライアン・トーマス
ムニヨス，ベニート
プラシツト，ペツピブーン
スターンズ，ブライアン・エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2005536507A publication Critical patent/JP2005536507A/ja
Publication of JP2005536507A5 publication Critical patent/JP2005536507A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2004521592A 2002-07-11 2003-07-08 ６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療 Pending JP2005536507A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39473402P 2002-07-11 2002-07-11
PCT/US2003/021493 WO2004006836A2 (en) 2002-07-11 2003-07-08 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds

Publications (2)

Publication Number Publication Date
JP2005536507A true JP2005536507A (ja) 2005-12-02
JP2005536507A5 JP2005536507A5 (enExample) 2006-04-20

Family

ID=30115760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004521592A Pending JP2005536507A (ja) 2002-07-11 2003-07-08 ６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療

Country Status (6)

Country Link
US (1) US7465730B2 (enExample)
EP (1) EP1539168A2 (enExample)
JP (1) JP2005536507A (enExample)
AU (1) AU2003248907B2 (enExample)
CA (1) CA2492022A1 (enExample)
WO (1) WO2004006836A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008149834A1 (ja) * 2007-05-31 2008-12-11 Kyowa Hakko Kirin Co., Ltd. ピリミドジアゼピノン誘導体
JP2016502545A (ja) * 2012-12-04 2016-01-28 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびそれらの用途

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047759A1 (es) 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
WO2007038684A2 (en) 2005-09-27 2007-04-05 Myriad Genetics, Inc. Pyrrole derivatives as therapeutic compounds
CN101003537A (zh) * 2006-01-17 2007-07-25 上海恒瑞医药有限公司 吡咯并哒嗪类衍生物及其制备方法和用途
MX2010003394A (es) 2007-09-28 2010-04-09 Daiichi Sankyo Co Ltd Derivado de gamma-aminoacido biciclico.
DK3106166T3 (da) 2008-02-29 2021-01-11 Vm Therapeutics Llc Forbindelser til behandling af smertesyndrom og andre lidelser
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
ES2635354T3 (es) 2009-03-26 2017-10-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de ácido gamma-amino bicíclico
JP5980780B2 (ja) 2011-06-08 2016-08-31 第一三共株式会社 クライゼン転位反応による二環性化合物の製造方法
CN103582622B (zh) 2011-06-08 2015-06-10 第一三共株式会社 经由亚胺鎓盐制备双环化合物的方法
KR101944575B1 (ko) 2011-12-15 2019-04-17 다이이찌 산쿄 가부시키가이샤 부제 촉매를 사용하는 2고리형 화합물의 광학 분할 방법
WO2013154066A1 (ja) 2012-04-10 2013-10-17 第一三共株式会社 酵素を用いる二環性化合物の光学分割方法
WO2014069626A1 (ja) * 2012-11-01 2014-05-08 協和発酵キリン株式会社 ピリミドジアゼピノン化合物の製造方法
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018100045A1 (en) * 2016-11-30 2018-06-07 Laboratorios Del Dr. Esteve, S.A. Ortho substituted phenylpyrazolo- and phenylpyrrolo-pyridazine derivatives having multimodal activity against pain
WO2018100041A1 (en) * 2016-11-30 2018-06-07 Laboratorios Del Dr. Esteve, S.A. Meta substituted phenylpyrazolo- and phenylpyrrolo- pyridazine derivatives having multimodal activity against pain
EP3630765A1 (en) * 2017-05-30 2020-04-08 Esteve Pharmaceuticals, S.A. Substituted pyrrolidinyl and piperidinyl pyrazolopyridazine derivatives having multimodal activity against pain
GB202106872D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
GB9726701D0 (en) 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6009043760, Ｊ．Ｏｒｇ．Ｃｈｅｍ．，（１９７７），４２（９），ｐ．１６３９−４４ *
JPN6009043762, Ｊ．Ｈｅｔｅｒｏｃｙｃｌｉｃ Ｃｈｅｍｉｓｔｒｙ，（１９７１），８（１），ｐ．１３−７ *
JPN6009044339, Ｃｈｅｍｉｋｅｒ−Ｚｅｉｔｕｎｇ，（１９８４），１０８（９），ｐ．２７５−８ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008149834A1 (ja) * 2007-05-31 2008-12-11 Kyowa Hakko Kirin Co., Ltd. ピリミドジアゼピノン誘導体
US7998954B2 (en) 2007-05-31 2011-08-16 Kyowa Hakko Kirin Co., Ltd. Pyrimidodiazepinone derivative
JP5345931B2 (ja) * 2007-05-31 2013-11-20 協和発酵キリン株式会社 ピリミドジアゼピノン誘導体
JP2016502545A (ja) * 2012-12-04 2016-01-28 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびそれらの用途

Also Published As

Publication number Publication date
CA2492022A1 (en) 2004-01-22
WO2004006836A2 (en) 2004-01-22
US7465730B2 (en) 2008-12-16
AU2003248907A1 (en) 2004-02-02
US20060154929A1 (en) 2006-07-13
EP1539168A2 (en) 2005-06-15
WO2004006836A3 (en) 2004-04-15
AU2003248907B2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
JP2005536507A (ja) ６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療
TWI458723B (zh) １，２－雙取代雜環化合物
DE60009033T2 (de) Tricyclische inhibitoren von poly(adp-ribose) polymerasen
DE69118388T2 (de) Substituierte bizyklische arylderivate mit selektiver leukotrien b4 antagonistischer wirkung
US8273762B2 (en) Hexahydro-pyrrolo-isoquinoline compounds
JPH11514668A (ja) ホスホジエステラーゼ（ｐｄｅ）ｉｖ型および腫瘍壊死因子（ｔｎｆ）阻害物質としての置換インダゾール誘導体及びその使用法
WO2009146696A1 (de) Verwendung von indol-3-carbonsäureestern zur hemmung der mikrosomalen prostaglandin e2 synthase
JPH0143747B2 (enExample)
KR20220029681A (ko) 특발성 폐 섬유증의 치료 방법
JPH09504519A (ja) ピリダジノキノリン化合物
JP2005516969A (ja) メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピロールモジュレーター
JPH09505030A (ja) ヒドロイソキノリン誘導体
AU650322B2 (en) Imidazopyridine PAF/H1 antagonists
WO2007114213A1 (ja) 置換二環式環状誘導体及びその用途
NZ238141A (en) 1,2,3,4,4a,10b-hexahydro-6-(sulphonamidophenyl)benzo(c)(1,6)naphthyridine derivatives, preparation and pharmaceutical compositions thereof
HUP9904623A2 (hu) 1H-Pirido[3,4-b]indol-4-karboxamid-származékok,eljárás előállításukra és alkalmazásuk a gyógyászatban
JP2008543782A (ja) ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト
HUP0301080A2 (hu) Helyettesített 1,2,3,4-tetrahidrokinolin-2-karbonsav-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE3650041T2 (de) Hemmung von Stoffwechselweg von 5-Lipoxygenasen.
US5693640A (en) Pyridazino-indole derivatives
JP2007512341A (ja) 神経障害性疼痛の治療に有用なピリジン−４−イルアミン化合物
JPH0236171A (ja) ジアリールエチレンジアミン誘導体およびそれらを含有する医薬組成物
US5580877A (en) Pyrazolo-quinoline derivatives for treating cerebral ischemia
JPS6293276A (ja) ２−置換キノリン
CN1720238B (zh) 神经活性化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100330